相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis
Ambra Pozzi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-γ in human proximal renal tubular cells
Xuan Li et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation
Sakiko Ohga et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia
Zhenglin Gu et al.
MOLECULAR PHARMACOLOGY (2007)
PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse
Anna C. Calkin et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-κB-dependent down-regulation of vascular cell adhesion molecule-1 expression
Ling Gao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor α
CW Park et al.
DIABETES (2006)
PPARγ gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats
S Lim et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose
U Panchapakesan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a
F Gizard et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Noradrenaline represses PPAR (peroxisome-proliferator-activated receptor) γ2 gene expression in brown adipocytes:: intracellular signalling and effects on PPAγ2 and PPARγ1 orotein levels
EM Lindgren et al.
BIOCHEMICAL JOURNAL (2004)
Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients
N Mitsuhashi et al.
ENDOCRINE JOURNAL (2004)
Weight loss-associated induction of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice
W Verreth et al.
CIRCULATION (2004)
Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat
T Tohma et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Modulation of PPARα expression and inflammatory interleukin-6 production by chronic glucose increases monocyte/endothelial adhesion
S Srinivasan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Relationship between peroxisome proliferator-activated receptors (PPARα and PPARγ) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats
N Kanie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model
SK Kim et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2003)
Cilostazol (Pletal®):: A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake
YG Liu et al.
CARDIOVASCULAR DRUG REVIEWS (2001)
Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose - Role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression
MR Sartippour et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
分享论文
